National manufacturer of
immunobiological products in Russia

Strategy

In December 2014, the Strategy of Development of FSUE NPO Microgen of the Russian Ministry of Health until 2020 was approved.

This is a long-time policy document, unique for NPO Microgen, which has been adopted for the first time since its establishment in 2003. A specific feature of the Strategy is the financial basis for the company’s development: the modernization requiring more than 10 billion rubles will be carried out at the cost of its own profit, without the non-returnable government funding.

According to the adopted Strategy, NPO Microgen will substantially revise its product portfolio to completely meet the needs of the National Calendar of Preventive Vaccination, to ensure import substitution with quality domestic preparations and to improve the efficiency of produced vaccines, blood products, bacteriophages etc.

The main objectives of implementation of the Development Strategy of NPO Microgen are the development, production and supply of immunobiological preparations in the “cold chain” regime under state, departmental or special programs, as well as in emergency situations throughout the Russian Federation and abroad. To increase the company’s profitability in order to generate its own financial resources for the company’s modernization. To ensure the compliance of the technological level of production with national and international requirements to the quality, safety and efficiency of products.

NPO Microgen’s Development Strategy will allow gradual modernization of the production capacities, improvement of the company’s quality and quantity indicators. It is planned that by 2020 the company will be able to achieve the level of performance required to supply the necessary volume of high quality and efficient domestic drugs to everyone who needs them.

At the first stage of the Strategy implementation the company’s activities will undergo the key changes: at the beginning state the product portfolio will be substantially revised, the management reshuffle will be conducted, new production lines arranged according to the international GMP standards will be commissioned.  

We would like to note that FSUE NPO Microgen of the Russian Ministry of Health is a strategically important enterprise in the sphere of national biological and epidemiological safety, it produces and supplies about 53% of vaccines included in the National Calendar of Vaccination and 95% epidemiological vaccines to all regions of Russia.